See more : Syntec Optics Holdings, Inc. (OPTXW) Income Statement Analysis – Financial Results
Complete financial analysis of Agree Realty Corporation (ADC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agree Realty Corporation, a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- The Siam Cement Public Company Limited (SCC-R.BK) Income Statement Analysis – Financial Results
- Companhia Habitasul de Participações (HBTS5.SA) Income Statement Analysis – Financial Results
- Mahindra Logistics Limited (MAHLOG.BO) Income Statement Analysis – Financial Results
- Freedom Acquisition I Corp. (FACT-WT) Income Statement Analysis – Financial Results
- Global Infotech Co., Ltd. (300465.SZ) Income Statement Analysis – Financial Results
Agree Realty Corporation (ADC)
About Agree Realty Corporation
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.50M | 463.15M | 363.61M | 248.57M | 187.48M | 148.20M | 116.56M | 91.53M | 69.97M | 53.56M | 43.52M | 35.79M | 36.32M | 36.11M | 37.26M | 35.65M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Cost of Revenue | 239.67M | 85.62M | 65.34M | 31.75M | 23.51M | 17.01M | 12.47M | 8.60M | 6.38M | 4.92M | 3.66M | 3.58M | 4.91M | 3.85M | 2.43M | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 297.83M | 377.53M | 298.26M | 216.82M | 163.97M | 131.18M | 104.09M | 82.93M | 63.59M | 48.64M | 39.86M | 32.21M | 31.41M | 32.26M | 34.83M | 35.59M | 34.47M | 32.91M | 31.58M | 29.93M | 27.47M | 25.82M | 24.68M | 23.73M | 21.93M | 19.67M | 18.23M | 16.29M | 13.80M | 9.50M |
| Gross Profit Ratio | 55.41% | 81.51% | 82.03% | 87.23% | 87.46% | 88.52% | 89.30% | 90.61% | 90.88% | 90.82% | 91.60% | 90.00% | 86.48% | 89.34% | 93.49% | 99.82% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.37 | 0.37 | 0.37 | 0.43 | 0.43 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 4.56M | 6.94M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 88.00 | -384.00 | 859.00K | -2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.79M | 30.12M | 25.46M | 20.79M | 15.57M | 12.17M | 9.95M | 8.02M | 6.99M | 6.63M | 5.95M | 5.68M | 5.66M | 5.00M | 5.42M | 4.36M | 4.46M | 4.02M | 4.19M | 2.85M | 2.28M | 2.01M | 1.81M | 1.56M | 1.42M | 1.17M | 1.11M | 1.10M | 1.00M | 700.00K |
| Other Expenses | 0.00 | 133.57M | 95.73M | 66.76M | 45.70M | 4.00K | 347.00K | 23.41M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 7.65M | 7.25M | 9.33M | 9.07M | 9.19M | 8.96M | 7.58M | 8.19M | 7.99M | 7.46M | 6.95M | 6.12M | 5.57M | 5.11M | -5.60M | -4.20M |
| Operating Expenses | 216.39M | 163.69M | 121.19M | 87.55M | 61.27M | 55.86M | 41.70M | 31.42M | 23.47M | 17.73M | 14.44M | 12.15M | 12.16M | 10.69M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Cost & Expenses | 283.11M | 249.31M | 186.53M | 119.30M | 84.78M | 72.87M | 54.17M | 40.02M | 29.85M | 22.65M | 18.10M | 15.73M | 17.07M | 14.54M | 14.63M | 19.37M | 13.79M | 13.09M | 13.38M | 11.81M | 9.86M | 10.20M | 9.79M | 9.02M | 8.37M | 7.29M | 6.67M | 6.21M | -4.60M | -3.50M |
| Interest Income | 0.00 | 63.44M | 50.38M | 40.10M | 33.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 770.18K | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.12M | 63.44M | 66.35M | 44.66M | 32.98M | 0.00 | 0.00 | 0.00 | 0.00 | 8.59M | 6.48M | 5.13M | 4.73M | 4.71M | 4.64M | 5.18M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 209.37M | 212.74M | 162.25M | 123.44M | 86.39M | 64.12M | 54.17M | 40.02M | 16.49M | 11.10M | 8.49M | 6.47M | 6.50M | 5.69M | 5.71M | 5.39M | 5.20M | 4.99M | 207.04K | 4.62M | 4.82M | 4.22M | 4.22M | 4.06M | 3.80M | 3.51M | 3.19M | 3.03M | 2.60M | 2.00M |
| EBITDA | 463.95M | 386.24M | 295.67M | 192.16M | 161.45M | 118.63M | 94.14M | 74.92M | 56.60M | 42.01M | 34.05M | 26.19M | 19.73M | 14.85M | 28.34M | 21.67M | 25.88M | 24.81M | 23.15M | 17.57M | 19.81M | 19.17M | 17.97M | 18.24M | 17.29M | 15.89M | 14.75M | 13.11M | 21.00M | 15.00M |
| EBITDA Ratio | 86.32% | 74.08% | 75.47% | 77.31% | 72.92% | 74.33% | 68.59% | 71.33% | 63.81% | 78.44% | 77.92% | 74.12% | 74.44% | 96.81% | 76.05% | 60.77% | 72.05% | 75.39% | 72.28% | 75.26% | 87.07% | 74.23% | 72.83% | 76.87% | 78.84% | 80.75% | 80.91% | 76.46% | 152.17% | 157.89% |
| Operating Income | 254.39M | 218.09M | 190.27M | 125.13M | 101.09M | 73.00M | 62.39M | 51.51M | 40.11M | 27.89M | 25.42M | 20.06M | 15.60M | 13.87M | 22.63M | 16.28M | 20.68M | 19.82M | 18.21M | 18.12M | 16.65M | 15.62M | 15.10M | 14.71M | 13.56M | 12.38M | 11.56M | 10.08M | 18.40M | 13.00M |
| Operating Income Ratio | 47.33% | 47.09% | 52.33% | 50.34% | 53.92% | 49.26% | 53.53% | 56.28% | 57.33% | 52.07% | 58.41% | 56.05% | 42.94% | 38.42% | 60.73% | 45.67% | 59.99% | 60.23% | 57.65% | 60.54% | 60.61% | 60.50% | 61.20% | 61.98% | 61.83% | 62.93% | 63.40% | 61.88% | 133.33% | 136.84% |
| Total Other Income/Expenses | -80.93M | -62.19M | -64.99M | -40.07M | -33.09M | -13.69M | -3.37M | -5.71M | -351.00K | -9.12M | -6.47M | -5.13M | 506.14K | -4.71M | 0.00 | -14.46M | 1.04M | -4.62M | 12.79K | -4.29M | 176.08K | 673.58K | 1.13M | 522.34K | 68.61K | 0.00 | 0.00 | 653.07K | 0.00 | 0.00 |
| Income Before Tax | 173.46M | 155.90M | 125.28M | 93.06M | 81.30M | 59.31M | 58.79M | 45.80M | 39.76M | 18.78M | 18.95M | 14.92M | 9.55M | 15.07M | 15.48M | 15.48M | 21.72M | 0.00 | 18.22M | 18.34M | 15.17M | 16.30M | 16.23M | 15.23M | 13.63M | 0.00 | 0.00 | 10.73M | 0.00 | 0.00 |
| Income Before Tax Ratio | 32.27% | 33.66% | 34.45% | 37.44% | 43.37% | 40.02% | 50.44% | 50.04% | 56.83% | 35.05% | 43.54% | 41.70% | 26.30% | 41.72% | 41.55% | 43.42% | 63.02% | 0.00% | 57.69% | 61.27% | 55.21% | 63.11% | 65.78% | 64.18% | 62.14% | 0.00% | 0.00% | 65.89% | 0.00% | 0.00% |
| Income Tax Expense | 2.91M | 2.86M | 2.40M | 1.09M | 538.00K | 516.00K | 4.62M | 6.39M | 1.10M | 8.87M | -728.73K | -3.13M | 9.70M | 6.51M | -9.83M | -13.20M | 5.20M | 5.84M | 6.58M | 5.00M | 7.14M | 6.85M | 6.82M | 7.61M | 6.75M | 6.29M | 6.34M | 6.35M | 15.20M | 12.70M |
| Net Income | 169.96M | 152.44M | 122.27M | 91.38M | 80.08M | 58.17M | 58.11M | 45.12M | 39.02M | 18.49M | 19.68M | 18.05M | 9.55M | 15.07M | 17.99M | 15.02M | 15.48M | 13.97M | 16.05M | 13.12M | 10.47M | 8.77M | 8.07M | 7.10M | 6.81M | 6.09M | 5.22M | 3.73M | 3.20M | 300.00K |
| Net Income Ratio | 31.62% | 32.91% | 33.63% | 36.76% | 42.71% | 39.25% | 49.86% | 49.29% | 55.77% | 34.52% | 45.21% | 50.43% | 26.30% | 41.72% | 48.29% | 42.12% | 44.92% | 42.46% | 50.82% | 43.85% | 38.12% | 33.97% | 32.68% | 29.91% | 31.04% | 30.94% | 28.63% | 22.92% | 23.19% | 3.16% |
| EPS | 1.70 | 1.84 | 1.79 | 1.76 | 1.96 | 1.81 | 2.09 | 1.97 | 2.17 | 1.24 | 1.51 | 1.63 | 0.99 | 1.54 | 2.20 | 1.91 | 2.02 | 1.84 | 2.15 | 2.03 | 1.63 | 1.99 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| EPS Diluted | 1.70 | 1.83 | 1.78 | 1.74 | 1.93 | 1.80 | 2.08 | 1.97 | 2.16 | 1.24 | 1.50 | 1.62 | 0.99 | 1.54 | 2.14 | 1.91 | 2.01 | 1.83 | 2.14 | 2.03 | 1.63 | 1.97 | 1.81 | 1.61 | 1.56 | 1.40 | 1.41 | 1.41 | 1.23 | 0.08 |
| Weighted Avg Shares Out | 95.19M | 78.66M | 66.80M | 51.84M | 40.58M | 32.07M | 27.63M | 22.87M | 18.00M | 14.88M | 13.07M | 11.07M | 9.64M | 9.76M | 7.90M | 7.68M | 7.65M | 7.59M | 7.46M | 6.46M | 4.88M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
| Weighted Avg Shares Out (Dil) | 95.44M | 79.16M | 67.14M | 52.40M | 41.22M | 32.40M | 27.70M | 22.96M | 18.07M | 14.97M | 13.16M | 11.14M | 9.68M | 9.76M | 8.42M | 8.38M | 7.72M | 7.64M | 7.50M | 6.46M | 5.26M | 4.45M | 4.42M | 4.41M | 4.36M | 4.36M | 3.69M | 2.65M | 2.60M | 3.21M |
2 REITs To Buy Before December 18th
The Fed is about to cut interest rates again. We think that this bodes well for REITs. Here are 2 REITs that we are buying ahead of December 18th.
Realty Income: What Could Turn The Tide?
Realty Income offers stable income but lacks recent capital appreciation. Management should focus on share buybacks to drive price appreciation. Diversified portfolio with more than 15,000 properties, but stepping outside core competencies has led to underperformance compared to Agree Realty....
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
Grab Magnificent Monthly Passive Income From 5 High-Yielding Quality Stocks
Most dividend investors seek solid passive income streams from quality dividend stocks.
Realty Income Vs. Agree Realty: Is The Valuation Gap Justified
Agree Realty and Realty Income are often compared due to their net lease, retail-oriented structure and attractive monthly dividends. A substantial outperformance Agree Realty has delivered over Realty Income over the last year has left many investors wondering whether that...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate...
Agree Realty: 3 Reasons To Sell And Buy Realty Income
Agree Realty Corporation stock has had a nice run-up over the past 6 months. The stock is now in the red zone on critical metrics. We discuss these and tell what looks better.
2 Top Dividend Stocks to Buy in December
With just a month left to the year, the S&P 500 is up 26% in 2024. Unless there's some major news over the next few weeks, the year will close out with a strong gain.
Agree Realty: Unfortunately No Longer A 'Buy' At This Price (Rating Downgrade)
Agree Realty is one of the more impressive triple-net lease REITs out there, with an upside that's non-trivial at the right valuation. That upside is no longer there, with the company trading far higher than when I bought it. As...
Source: https://incomestatements.info
Category: Stock Reports